Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year, » Read more about: Massive Upside In Big Money Pharma Favorite? »
Read More
Got $20,000? How to Invest Today
» Read more about: Got $20,000? How to Invest Today »
Read More
1 Cheap Blue Chip Stock To Buy Before It Pops
When it comes to investing, finding a stock with a history of success while providing minimal risk is considered the holy grail.
For those looking for a blue chip stock with growth potential, an excellent place to start is with one of the world’s most consistent performers: Berkshire Hathaway.
Berkshire Hathaway was founded in 1839 and had a rich history of success in the financial markets.
» Read more about: 1 Cheap Blue Chip Stock To Buy Before It Pops »
Read MoreBull Vs Bear Case for Apple
Apple (AAPL) has created an unparalleled ecosystem, consistently reports strong financials, and has ultra-loyal customers — collectively resulting in a wide moat. Considering shares are down around 25% year to date, it may be a tempting buy, but could the tech giant’s stock dip even further?
» Read more about: Bull Vs Bear Case for Apple »
Read More
1 Cloud SaaS Healthcare Stock to Buy on the Dip?
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Why This Beverage Giant Can’t Be Toppled
A famous book on business was titled Barbarians at the Gate, documenting the leveraged buyout of RJR Nabisco. If nothing else, it highlights how just the sniff of an opportunity to make money can drive money seekers to make wild decisions.
Some giant businesses have been on the receiving end of similar threats to their solvency as invaders attempt to take their share.
» Read more about: Why This Beverage Giant Can’t Be Toppled »
Read MoreThe Daily
Billionaire George Soros Pours $644,823,000 Into Apple, Amazon and One Stock That Warren Buffett Recently Jumped Into
Billionaire investor George Soros has opened hundreds of millions of dollars in new positions in mega-cap stocks, including Apple (AAPL) and Amazon (AMZN).
A new 13F filing with the Securities and Exchange Commission (SEC) shows Soros Fund Management bought more than 1.843 million shares of Amazon worth $404.808 million in Q3 of 2025.